Company:  AGENUS INC (AGEN)
Form Type:  4
Filing Date:  3/20/2017 
CIK:  0001098972 
Address:  3 FORBES ROAD 
City, State, Zip:  LEXINGTON, Massachusetts 02421 
Telephone:  781-674-4410 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.02  
Change: 
0.27 (7.20%)  
Trade Time: 
Nov 22  
Market Cap: 
$402.74M
Trade AGEN now with 

© 2017  
Description of Business
We are a clinical-stage immuno-oncology ("I-O") company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. Our approach to cancer immunotherapy involves a diverse portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. We, in collaboration with our partners, have developed a number of immuno-modulatory antibodies against important nodes of immune regulation. These include antibodies targeting CTLA-4, GITR and OX40 that are in clinical development, and our anti-PD-1 antibody anticipated to enter the clinic in the first half of 2017. Our discovery pipeline includes a number of proprietary checkpoint modulating ("CPM") antibodies against innovative targets such as TIGIT and 4-1BB (also known as CD137). We believe that tailored combination therapies are essential to combat some of the most resistant cancers.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES